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1. Introduction 
Information is presented pertaining to the characteristics of multiple sclerosis (MS) 
including bowel dysfunction that consists of constipation, fecal incontinence or both 
constipation and fecal incontinence. Bowel functions and its neural control, prevalence and 
symptoms of constipation and fecal incontinence that is characteristic of persons with MS 
together with a description of procedures for assessment and intervention strategies are 
presented. The outcomes of bowel interventions and their effects on the quality of life of 
persons with MS together with suggestions for further research are also presented.  
2. Characteristics of Multiple Sclerosis 
Multiple Sclerosis (MS) is an inflammatory and demyelinating autoimmune disorder 
(Herndon, 2003) that affects approximately 2.5 million people worldwide (Moses, Picone & 
Smith, 2008) that has an approximately 2:1 female to male ratio (Willer, Dyment, Risch, 
Sadovnick, & Ebers, 2003). This disease of the central nervous system (CNS) affects nerve 
pathways in the brain and spinal cord. MS is thought to be acquired through the complex 
interaction of genetic and environmental factors (Goodin, 2010). Environmental influences 
are thought to include low levels of ultraviolet radiation and vitamin D, viruses, and non 
infectious agents such as smoking and psychological stress (Milo & Kahana, 2010; Sloka, 
Silva, Pryse-Phillips, Meta & Wee Yong, 2011; Carlye, 1997; Mehta, 2010; Koch-Henrikson & 
Sorensen, 2010). 
The onset of MS generally occurs during young adulthood (Weinshenker, 1993) and is 
usually characterized by an initial relapsing and remitting course followed by a progressive 
course (Wienshenker, 1998; Vukusic & Confavreux, 2007). As a result of impairment of the 
CNS bowel dysfunction is one of many symptoms experienced by persons with MS that 
consists of constipation and fecal incontinence. Constipation, defined as two or fewer bowel 
movements per week, the need to manipulate the rectum digitally to facilitate defecation all or 
most of the time, and/or use of laxatives, enemas, or suppositories more than once a week, has 
a prevalence rate between 43% and 73% in the MS population (Hinds, Eidelman & Wald, 1990; 
Nordenbo, Andersen, & Andersen, 1996). Fecal incontinence, defined as uncontrolled or 
involuntary emissions of flatus and/or stools, has a prevalence of between 51% and 53% in the 
MS population (Hinds et al. 1990; Nordenbo et al. 1996).  
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3. Bowel functions and neural control 
Principal functions of the colon include 1) absorption of water and electrolytes from the 
chime, ingested food that is mixed with stomach secretions that pass into the small intestine 
and on to the large intestine, and 2) storage of fecal matter until it can be expelled (Guyton & 
Hall, 2006). Mixing movements known as haustrations promote absorption of fluid and 
dissolved substances causing the chime to become a semisolid slush. Haustral contractions 
propel the material in the colon toward the rectum. Beginning of the transverse colon and 
continuing to the sigmoid, mass movements mainly take over the propulsive role which 
occur only one to three times each day and most frequently for 15 minutes during the first 
hour after eating breakfast. Mass movements are facilitated by the gastrocolic and 
duodenocolic reflexes that result from distention of the stomach and duodenum via extrinsic 
nerves of the autonomic nervous system. When a mass movement forces feces into the 
rectum, the desire for defecation is normally initiated, including reflex contraction of the 
rectum and relaxation of the anal sphincters. Loss of fecal matter through the anus is 
prevented by tonic contraction of the internal and external anal sphincters. The external 
sphincter is controlled by nerve fibers in the pudendal nerve which is under voluntary 
conscious control. Defecation is initiated by defecation reflexes and is fortified by the 
parasympathetic defecation reflex that involves the sacral segments of the spinal cord. 
Conscious relaxation of the internal sphincter and forward movement of feces toward the 
anus normally initiate contraction of the external sphincter which prevents defecation and if 
kept contracted defecation reflexes die out after a few minutes and remain quiescent for 
several hours or until additional amounts of feces enter the rectum (Guyton & Hall, 2006). 
The autonomic nervous system, consisting of sympathetic and parasympathetic nerve fibers, 
controls the visceral functions pertaining to gastrointestinal mobility and secretion and is 
activated mainly by centers located in the spinal cord, brain stem and hypothalamus 
(Guyton & Hall, 2006). Sympathetic nerves originate in the spinal cord between segments T-
1 and L-2 and pass from here into the sympathetic chain and then to the tissue and organs 
that are stimulated by the sympathetic nerves. Sympathetic fibers from cord segments T-7 
through T-11 pass into the abdomen. Sympathetic nerve endings secrete norepinephrine and 
have two major types of adrenergic receptors: alpha and beta. Alpha receptors cause 
intestinal relaxation, intestinal sphincter contraction, and bladder sphincter contraction. Beta 
receptors cause intestinal and uterus relaxation and bladder wall relaxation. Autonomic 
reflexes that inhibit gastrointestinal activity that severely block movement of food through 
the intestines are initiated by sensory signals that pass to the prevertebral sympathetic 
ganglia or to the spinal cord and then are transmitted through the sympathetic nervous 
system back to the gut (Guyton & Hall, 2006).  
Parasympathetic fibers leave the CNS through cranial nerves III, VII, IX, and X; and the 
second and third sacral spinal nerves; and the first and fourth sacral nerves (Guyton & Hall, 
2006). The vagus, cranial nerve X, supplies parasympathetic nerves to the proximal half of 
the colon. The sacral parasympathetic fibers congregate in the pelvic nerves which leave the 
sacral plexus at S-2 and S-3 levels and distribute their peripheral fibers to the descending 
colon, rectum, and external genitalia. Parasympathetic nerve endings secrete acetylcholine 
which increases the overall activity of the gastrointestinal tract by promoting peristalsis and 
relaxing the sphincters to allow rapid propulsion of contents along the tract and is 
associated with increases in rates of secretion by many of the gastrointestinal glands. 
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However, strong sympathetic stimulation inhibits peristalsis and increases the tone of the 
sphincters resulting in greatly slowed propulsion of food through the tract and sometimes 
decreases secretion as well (Guyton & Hall, 2006). Figure 1 illustrates bowel anatomy and 
neural components associated with bowel function. 
Hypothalamic centers can control gastrointestinal activity. Thus, autonomic centers in the 
brain stem act as relay stations for control of activities initiated at higher levels of the brain. 
Higher areas of the brain can alter all or portions of the autonomic system to cause 
constipation. 
4. Constipation  
Constipation can be primary or secondary (Candelli, Nista, Zocco, & Gasbarrini, 2001). 
Primary constipation, also known as idiopathic or functional constipation, is considered 
when no definite cause is found and specific diseases cannot be demonstrated. Constipation 
is considered secondary when specific causes are recognized such as poor fiber diet, 
intestinal neoplasm, drugs, or specific diseases such as multiple sclerosis. Constipation in 
MS patients can be caused either by slow colonic transit, abnormal rectal function, or 
abnormal pelvic floor function (Chia, Fowler, Kamm, Henry, Lemieux & Swash, 1995; 
DasGupta & Fowler, 2003; Weber, Grise, Roquebert, Hellot, Mihout, Samson, Beuret-
Blanquart, Pasquis &Denis, 1987).  
Slow transit constipation is characterized by prolonged delay in the transit of stool through 
the colon due to a primary dysfunction of the colonic smooth muscle or its nerve 
innervations (Rao, 2007). Symptoms may include straining during defecations, lumpy or 
hard stools, sensation of incomplete evacuation of stool, sensation of anorectal obstruction 
of stool, and manual maneuvers to facilitate defecation. Pathologic conditions include phasic 
colonic motor activity; diminished gastrocolonic response following a meal; the high 
amplitude, prolonged duration, propagated contractions are decreased; and the velocity of 
propagation is slower, waves have a greater tendency to abort prematurely, and their 
amplitude is also decreased (Rao, 2007). Weber et al. (1987) in a study of 16 MS patients 
reported that transit times of radiopaque markers led to an objective confirmation of 
constipation in 13 of the 15 patients. Interruption of sympathetic innervations from the 
dorsolumbar spinal cord via the superior mesenteric ganglion and vagal parasympathetic 
innervations to the right colon together with sympathetic innervations from the 
dorsolumbar spinal cord via the inferior mesenteric ganglion and parasympathetic 
innervations from the sacral spinal cord via the erigentes nerves to the left colon were 
proposed to explain the decreased transit observed in MS patients (Weber et al. 1987). Wald 
(1986) reported that prolonged transit time throughout the entire colon among MS patients 
responded poorly to treatment compared to those characterized by slow transit restricted to 
the left colon or delay only through the anorectal structures. 
Abnormal rectal function, also known as dyssynergic defecation, obstructive defecation, 
anismus, pelvic floor dyssynergia, or outlet obstruction, is characterized by difficulty to 
expel stool from the anorectum (Rao, 2007). Symptoms include the need to strain excessively, 
feeling of incomplete evacuation, abdominal fullness or bloating, and need to use fingers to 
facilitate defecation (Rao, Tuteja, Vellema, Kempf & Stessman, 2004). Dyssynergic defecation 
may be caused by paradoxical anal contraction or involuntary anal spasm during defecation 
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Fig. 1. Bowel anatomy and neural components associated with bowel function  
(Rao, 2007). Munteis, Andreu, Martinez-Rodriquez, Ois, Bory & Roquer, (2008) reported that 
32 MS patients with constipation compared to 22 patients without neurological or 
gastroenterologic abnormalities had significantly lower squeeze maximal sphincter pressure 
and higher anal inhibitory reflex, conditions that impede defecation. Women with pelvic 
organ prolapse and who reported chronic straining to defecate reportedly have a high risk 
C-1
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for constipation (Arya, Novi, Shaunik, Morgan & Bradley, 2005). The authors theorized that 
chronic straining may produce weakness of the pelvic floor resulting in pudendal nerve 
injury with loss of tonicity of pelvic floor muscles and subsequent development of prolapse. 
5. Fecal incontinence 
Fecal incontinence is characterized by an urgent need to defecate and loss of stool. Major 
factors causing fecal incontinence among MS patients include the lack of voluntary control 
of the external anal sphincter, rectal hyperreactivity, reduced rectal tone and contractility 
causing fecal impaction and rectal distension, and reduced or lost anal sensibility (Chia, et 
al. 1995; Hennessey, Robertson, Swingler & Compston, 1999; Krogh & Christensen, 2009). 
Studies among persons with MS have shown that fecal incontinence is associated with 
reduced rectal sensation, a markedly reduced external sphincter function, weakness of 
pelvic floor musculature and an inability to close the anorectal angle (Nordenbo, et al. 1995; 
Waldron et al. 1993). Causes of fecal incontinence unrelated to MS include diarrheal 
infections due to viral, bacterial, and protozoal agents (Walker, 2006); food allergy (Walker, 
2006); or pudendal nerve damage associated with childbirth (Swash, Snooks & Chalmers, 
1987). 
6. Assessment of bowel dysfunction 
Bowel problems particularly fecal incontinence is often withheld from sharing the problem 
with health care providers due to feelings of embarrassment or shame (Khan, Pallant, Shea 
& Whishaw, 2009; Powell & Rigby, 2000; Wald, 2007). Therefore, since bowel dysfunction is 
relatively common among persons with MS it is important for health care providers to ask 
their MS patients in a careful supportive manner about their bowel function as accurate 
assessment of the presenting bowel problem is key to the successful treatment and 
management of bowel dysfunction (Irwin, 2003). Important bowel assessment information 
needed by the health care provider can be obtained through periodically patient-
administered surveys and/or through patient interviews. A description of several patient-
administered survey questionnaires are described below. 
6.1 Instruments used to assess bowel function/dysfunction 
Patient-administered questionnaires regarding their bowel function or dysfunction can 
provide health care providers with information that can assist them in determining 
appropriate treatment, counseling, or needed referrals. Periodic assessments are important 
to determine if the current treatment is effective or in need of change. Periodic assessments 
are also needed because of possible change in the patient’s disability status that may 
increase bowel problems (Wiesel, Norton, Glickman, & Kamm, 2001). Several patient-
administered questionnaires are described below. 
6.1.1 The Bowel Function Questionnaire for Persons with Multiple Sclerosis (BFQ-MS)  
The BFQ-MS, developed for persons with MS, is a patient-administered scale that consists of 
15 items pertaining to constipation, 13 items pertaining to fecal incontinence and 20 items 
pertaining to both constipation and fecal incontinence (Gulick, 2010). The questionnaire 
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items inquire about one’s medical/surgical background that may be related to bowel 
dysfunction; medications with constipating or diarrheal effects; symptoms (frequency, 
consistency, time spent on the toilet, amount of time once the urge is felt before defecation 
occurs, skin breakdown around anus or perineum, pain/discomfort on defecation, 
flatulence, strain to defecate, feel bowel is not empty after defecation); nondrug 
interventions; drug interventions; and improvement or worsening over time. The items are 
rated on a Likert scale that ranges between 0 and 5 with higher scores indicating a 
worsening of bowel problems. Cronbach alpha reliability coefficients for the Constipation, 
Fecal Incontinence, and both Constipation and Fecal Incontinence subscales were 0.70, 0.68, 
and 0.69, respectively. The three subscales demonstrate satisfactory validity as they were 
able to differentiate symptom and treatment differences between the three types of bowel 
dysfunction. 
6.1.2 The Quality of Life Scoring Tool Relating to Bowel Management (QOL-BM)  
The QOL-BM, originally developed for use with spinal cord injured patients (Slater, 2003), 
was tested for reliability and validity with a sample of 502 persons with MS (Gulick, 2011). 
Principal component analysis and Varimax rotation factor analysis of the 11-item scale used 
with MS patients resulted in two factors: Management and Relationships. The 6-item 
Management subscale consists of items related to severity of bowel difficulty, 
convenience/inconvenience of bowel care, and satisfaction with bowel care. The 5-item 
Relationships subscale consists of items related to worry about bowel accidents, personal 
relationships and social activity. Internal consistency reliability for the total scale was 0.90 
and was 0.86 for the Management subscale and 0.83 for the Relationships subscale 
suggesting satisfactory reliability. Discriminant validity was shown for the total and 
subscales based on the MS patient’s disability level (p < .05). 
6.1.3 Constipation Symptom Assessment Instrument (PAC-SYM)  
The PAC-SYM is a constipation symptom assessment scale consisting of 12 items that 
measure stool symptoms, rectal symptoms and abdominal symptoms (Frank, Kleinman, 
Farup, Taylor & Miner, 1999). Items are rated on a 5-point Likert scale from absence of 
symptoms (0) to very severe (4). Internal consistency (Cronbach’s alpha = 0.89) and test-
retest reliability (intraclass correlation = 0.75) were high. Within subject change over a 6-
week period demonstrated significantly improved scores. The PAC-SYM scale has been 
used with opium-induced constipation patients (Slappendel, Simpson, Dubois & Keininger, 
2006) and with women with pelvic organ prolapse and constipation (Arya et al. 2005).  
6.1.4 The Brief Fecal Incontinence Score 
The Brief Fecal Incontinence Score is a 7-item scale that measures frequency of stool, stool 
consistency, flatulence, altered lifestyle, drug and nondrug interventions, and inability to 
defer defecation for 15 minutes (Vaizey, Carapeti, Cahill & Kamm, 1999). A five-point Likert 
rating scale from Never (0) to Daily (5) is used. The scale correlated closely with clinical 
assessment (r=0.79), showed high test-retest reliability (r=0.87), and showed sensitivity to 
change from pre-surgery to 6-weeks post-surgery (p<0.004) suggesting good reliability and 
validity. The scale has not reportedly been used with MS patients. 
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6.2 Patient interview regarding bowel function/dysfunction 
One or more of the survey questionnaires could be used prior to conducting an interview 
with the patient. Suggested questions to be asked during the patient interview are described 
in Table 1. General questions are presented and depending on the individual’s response 
more detailed questions can be explored.  
A follow-up to the interview questions includes a physical assessment, described below, to 
determine if abnormalities of the anorectum and perineum can be detected. 
6.3 Physical assessment and laboratory tests pertaining to bowel dysfunction 
The following examinations are recommended to assist in identifying underlying causes of 
bowel dysfunction (Hinds & Wald, 1989; Irwin, 2002; Namey & Halper, 2000). 
1. Abdominal assessment by palpating along the course of the colon to detect any mass or 
tenderness  
2. Rectal and pelvic exam to look for prolapse, rectocele, hemorrhoids, fissures, and fecal 
impaction 
3. Digital assessment of resting anal tone and external sphincter pressures 
4. Digital assessment to obtain stool sample for testing for occult blood 
5. Puborectalis function by hooking the examining finger posteriorly onto the puborectalis 
bar and feeling the muscle contract when the patient squeezes and relaxes when asked 
to strain 
6. Check perineum for skin condition 
7. Blood work should include blood glucose, electrolytes, calcium, and if necessary, 
thyroid function (Hinds & Wald, 1989) 
Information obtained from the interview, physical assessment and blood work should guide 
the development of an individualized bowel program. 
7. Interventions to control bowel function/dysfunction 
7.1 Basic bowel program: Constipation 
Development of the bowel program should be comprehensive and individualized to include 
the physical abilities of the patient, availability of care, the chosen lifestyle and preferences 
of the patient and education of the patient and caregiver (Coggrave, Wiesel & Norton, 2006). 
The approach to treating bowel problems in MS should be guided by an evaluation of likely 
pathophysiology of the bowel symptoms (Hay-Smith, Siegert, Weatherall & Abernethy, 
2007). Simple and conservative approaches of a bowel program include appropriate diet and 
fluid intake, awareness of medications that may have a constipating or diarrheal effect, 
active or passive exercise, and toileting regime.  
7.1.1 Diet and fluid intake 
Good nutrition is vital for one’s overall health and for a 1800 calorie diet the 
recommendations include a daily intake of 1 ½ cups of fruit, 2 ½ cups of dark 
green/orange/red vegetables, 6 ounces of grains, 5 ½ ounces of meat and beans, 3 cups of 
milk, 24 grams of oils, and 20-30 grams of fiber (Dietary Guidelines for Americans-2010). A 
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1. Tell me about your bowel movements during the past week. 
2. How frequently do you move your bowels during the week? 
    Is this your typical pattern?  Are you satisfied with this pattern? 
3. Are your bowel movements usually liquid, loose, soft, hard, lumpy or does the 
    stool consistency vary? 
4. Now ask questions shown below according to reported stool consistency. 
Stools usually Liquid or Loose Stools Usually Hard or Lumpy 
1. Do you lose some or all of the stool  
     before making it to the toilet? If yes,  
     when and where does this occur? 
1. Do you strain to pass your stool? 
     If yes, what is the frequency? 
2. What things have you done to help  
     control loss of stool. Tell me about  
     them. 
2. Do you feel your bowel is not empty 
    or need to go again quickly? 
   If yes, what is the frequency? 
3. Do you use medications to help you 
    control loss of stool or bowel     
    leakage?  Tell me about them. 
3. What things have you done to help  
    you move your bowels? 
    Tell me about them. 
4. Do you have any food allergies? 
    If yes, tell me about them. 
4. Do you use laxatives, suppositories,  
    or enemas to help with bowel care? 
   Tell me about them. 
Additional background questions to ask pertaining to possible causes of bowel 
dysfunction and toileting facilities 
  1. How long have you experienced your bowel problem? 
  2. What medications are you currently taking other than laxatives or anti- 
      diarrheal agents? 
  3. Tell me about the foods you usually eat and the type and amount of beverage  
      each day. 
  4. Do you experience pain or discomfort when moving your bowels? 
  5. Do you need assistance from other persons to help you with bowel care? 
  6. Are toilet facilities readily available and comfortable? 
  7. How much does your bowel problem bother you and interfere with every  
      day activities? 
  8. Are there conditions that may be related to your current bowel problem? 
          Surgical procedures: abdomen, rectal, anal, or perineum 
          Difficult childbirth (woman) 
          Medical conditions such as colitis, Crohns disease 
          Failure to heed the urge to move your bowels 
          Sexual abuse 
          Medications with constipating or diarrheal effects 
  9. Is there a family history of bowel problems? 
10. Is there anything else you’d like to tell me about your bowel problem? 
Table 1. Interview Regarding Bowel Functions/Dysfunctions 
common cause of constipation is a diet low in fiber. Fiber may be soluble that dissolves 
easily in water and takes on a gel-like texture in the intestine or insoluble fiber that passes 
through the intestine almost unchanged. Together, the bulk and soft texture of fiber helps 
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prevent hard, dry stools (Rigby & Powel, 2005). However, based on a meta-analysis of 
studies of the effect of fiber treatment on bowel function, Muller-Lissner (1988) concluded 
that there is no justification for claiming rye bran, a form of insoluble fiber, given to patients 
with constipation can return stool output and transit time to normal since there may be a 
motility disorder of the colon which is primary or secondary to an underlying disease or an 
altered lifestyle that is responsible for constipation. 
The addition of high fiber foods to one’s diet has mixed results. A study of 41 women with 
pelvic floor disorder given slow increases of high-fiber cereal until 28 grams were reached 
over a 42 day period resulted in withdrawal of 11 patients largely due to inability to tolerate 
the fiber diet (Shariati, Maceda & Hale, 2008). The 30 patients who completed the study 
reported significant decreases in adominal pain and bloating, painful bowel movements, 
rectal bleeding, incomplete bowel movements, consistency of stool, straining or squeezing, 
laxative use, vaginal and/or perineal splinting. Increasing fiber to one’s diet should be 
introduced slowly in order to control for symptoms of bloating and gas. The addition of 
yoghurt containing Lactobacillus GG along with a fiber rich diet can decrease 
gastrointestinal symptoms associated with a fiber rich diet (Hongisto, Paajanen, Saxelin & 
Korpela, 2006). A list of fiber foods together with the standard serving size and grams of 
fiber identified by the USDA and USDHHS (2010) are presented in Table 2. 
7.1.2 Medications that can adversely affect bowel dysfunction 
Control of various MS-related symptoms or other non-MS conditions such as hypertension 
may require medications that have constipating affects. A list of these medications is shown 
in Table 3. Patients need to be queried about the medications that they currently are taking 
to determine if any of them have constipating and/or diarrheal effects.  
7.1.3 Physical activity to promote bowel function   
Body movement through exercise helps promote peristalisis of the colon, that may reduce 
the likelihood of constipation (Petajan , Gappmaier, White, Spencer, Mino & Hicks, (1996). 
Exercise may be passive or active depending on the disability status of the person with MS. 
Physical activity may be increased according to functional level by performing activities of 
daily living, pursuing more active recreation and eventually developing a structured 
exercise program (Petajan & White, 1999). Several studies with persons with MS given 
aerobic training and fitness (Petajan et al. 1996) or extended outpatient rehabilitation 
program (Di Fabio, Soderberg, Choi, Hansen & Schapiro,1998) demonstrated improvement 
in the study participants’ bowel functioning. A study by Gulick and Goodman (2006) 
evaluated the effect of everyday activities performed in and around the home among 123 
persons with MS ranging between mild to severe disability. After controlling for disability 
level, bowel and bladder symptoms increased with increased levels of physical activity. 
7.1.4 Toileting regime to assist in bowel evacuation 
A number of activities related to toileting can aid defecation. Planning the toileting routine 
during the first hour following breakfast takes advantage of increased peristalsis of the 
colon which moves the chime/feces into the sigmoid colon and rectum (Guyton & Hall, 
2006). Patients who are able to sit safely and tolerate sitting on a commode or toilet for short  
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Food Standard Portion Size Dietary Fiber in  
Standard Portion (g) 
Grains 
   Bran ready-to-eat cereal 
   (100%) 
1/3 cup (about 1 ounce) 5.6-8.1
   Plain rye wafer crackers 2 wafers 5.0
   Bran ready-to-eat cereals 
   (various) 
1/3-3/4 cup (about 1 ounce) 2.6-5
   Whole wheat English muffin 1 muffin 4.4
   Soybeans, green, cooked ½ cup 3.8
   Shredded wheat ready-to-eat 
   cereal 
½ cup (about 1 ounce) 2.7-3.8
   Whole wheat spaghetti, cooked ½ cup 3.1
   Oat bran muffin 1 small 3.0
   Pearled barley, cooked ½ cup 3.0
Vegetables 
   Artichoke, cooked ¼ cup hearts 7.2
   Green peas, cooked 1/2 cup 3.5-4.4
   Mixed vegetables, cooked ½ cup 4.0
   Sweet potato, baked in skin 1 medium 3.8
   Greens (spinach, collards, 
   turnip  greens), cooked
½ cup 2.5-3.5
   Sauerkraut, canned ½ cup 3.4
   Potato, baked, with skin 1 small 3.0
   Broccoli, cooked ½ cup 2.6-2.8
Fruit 
   Asian pear 1 small 4.4
   Raspberries ½ cup 4.0
   Blackberries ½ cup 3.8
   Prunes, stewed ½ cup 3.8
   Figs, dried ¼ cup 3.7
   Apple, with skin 1 small 3.6
   Banana 1 medium 3.1
   Orange 1 medium 3.1
   Strawberries 1 cup 3.0
   Guava 1 fruit 3.0
   Dates ¼ cup 2.9
Lentils and Nuts
   Beans (navy, pinto, black, 
   kidney, white, great  
   northern,  lima), cooked
½ cup 6.2-9.6
   Split peas, lentils, chickpeas, 
   or cowpeas, cooked
½ cup 5.6-8.1
   Soybeans, mature, cooked ½ cup 5.2
   Almonds    1 ounce 3.5
Table 2. Selected Food Sources Ranked by Standard Food Portion and Amounts  of Dietary 
Fiber 
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Drugs with Constipating Effects  
      Analgesics (including non-steriodal anti-inflammatory drugs) 
      Antacids (e.g., aluminum and calcium compounds) 
      Anticolinergics (e.g., Oxybutynin, Ditropan(R)) 
     Anticonvulsants (e.g.,  oxcarbazepine, Trileptal(R))  
     Antidepressants (e.g., selective serotonin reuptake inhibitors) 
     Antihypertensives ( e.g., clonidine, Catapres(R)) 
     Antimotility (e.g., Loperamide, Imodium(R)) 
     Anti-Parkinsonism (e.g., Sinemet, Carbidopa, Lodosyn(R)) 
     Antispastic (eg.Clonide, Catapres(R)) 
     Diuretics (e.g., hydrochlorothiazide) 
     Hematinics (e.g., Iron) 
     Laxatives (long term use) 
     Opiates (e.g., Morphine, Codeine) 
     Psychotherapeutic drugs (e.g., Thioridazine,  Mellaril(R)) 
Drugs with Diarrheal Effects 
     Antacids containing magnesium 
     Antibiotics 
     Antidepressant (e.g., Sertraline, Zoloft(R)) 
     Antihypertension (e.g., Captopril, Capoten(R)) 
     Chemotherapy drugs 
     Nonsteroidal anti-inflammatory drugs, Ibuprofen, Motrin® 
Table 3. Medications Containing Constipating or Diarrheal Effects 
periods and lean forward to bring pressure onto the colon may promote defecation 
(Lewicky-Gaupp et al. 2008; Pierce et al. 2001). Toilet facilities must be readily accessible and 
comfortable. The need for toilet assistance from caretakers as well as their attitude towards 
bowel care needs to be assessed (Irwin, 2003). 
7.2 Other components of a bowel program: Constipation 
Some persons with MS may benefit from other forms of bowel control depending on their 
disability level and comfort of the particular procedure. These include abdominal massage, 
biofeedback, anal stimulation, digital removal of feces, and rectal or trans-anal irrigation. 
Various laxatives may be used and/or enemas. Gastroenterology referrals may be indicated 
for some persons with MS. 
7.2.1 Abdominal massage 
Abdominal massage reportedly aids peristalsis of the colon to enhance the mass movement 
of the gut and increases the strength of the contractions and propulsion force through 
sensory stimulation of the parasympathetic division (McClurg, Hagen, Hawkins & Lowe-
Strong, 2010). This stimulation increases the mobility of the muscles to the gut, increases 
digestive secretions and relaxes the sphincters in the rectoano region. McClurg, using 
abdominal massage instruction over a four week period given to 15 MS patients compared 
to 15 MS patient controls with an EDSS disability score between 2.5-6.0 (mean = 3.5) resulted 
in improved frequency of defecation from 2 to 4.5 defecations per week, decreased time 
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spent defecating from 10 minutes to 6 minutes for the experimental group compared to 12 to 
10 minutes per day for the control group. Consistency of stools for both the experimental 
and control groups was softer at the end of the four week period compared to baseline. 
7.2.2 Biofeedback for constipation 
Biofeedback represents a number of behavioral modification techniques, which, when 
applied to treatment of constipation and fecal incontinence, may include sphincter exercises, 
bowel habit retraining, counseling, health education and use of medications (Wiesel, 
Norton, Roy, Storrie, Bowers & Kamm, 2000). In a study of 18 persons with MS given 
biofeedback instruction for anorectal dysfunction, improvement was shown in 8 (44.4%) of 
the MS patients given biofeedback who had milder manometric abnormalities (squeeze 
maximal sphincter pressure, anal inhibitory reflex, and paradoxical contraction of the 
puborectal musculature) and limited disability (Munteis et al. 2008). 
7.2.3 Anal stimulation 
The defecation reflex can be stimulated by dilating the anus with a lubricated gloved finger. 
This procedure stimulates the anal sigmoid reflex which causes the colon to contract, the 
anus relaxes, and fecal contents can be pushed out and is most effective if performed when 
the patient is in a sitting position (Pierce, et al. 2001). 
7.2.4 Digital removal of feces 
Digital removal of feces may be performed by patients themselves or by nurses who have 
received specialized training in the performance of digital removal of feces (Kyle, et al. 
2005). However, this procedure should only be used as the last resort and after all other 
methods of bowel evacuation have failed (Powell & Rigby, 2000). Because of the invasive 
nature of the procedure patient consent is needed for health care providers to perform the 
procedure. 
7.2.5 Rectal or trans-anal irrigation 
This procedure involves a process of facilitating evacuation of feces from the bowel by 
passing water or other liquids in to the bowel via the anus in a quantity sufficient to reach 
beyond the rectum (Coggrave, 2008). The infused water distends the rectal wall and 
stimulates the stretch receptors to stimulate defecation (Pellatt, 2007). 
7.2.6 Laxatives, suppositories and enemas 
Persons with MS use a range of interventions to help manage the symptoms of constipation, 
fecal incontinence and/or both constipation and fecal incontinence, with varying degrees of 
success. A list of medications used for constipation together with their action and either 
precautions or contraindications (Curry Jr. & Butler, 2006) are presented in Table 4. Close 
monitoring of the frequency and duration of laxative use can be beneficial in determining 
whether normal bowel habits are reestablished between bouts of constipation or if a more 
severe condition exists (Curry & Butler, 2006). 
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7.2.7 Gastroenterology referrals  
Although most patients with chronic constipation can usually be treated successfully in the 
primary care setting, some patients may require referral to a gastroenterologist. Reasons for 
referral include suspicion of defecatory disorders such as pelvic floor dyssynergia, lack of 
sufficient response to empiric treatment, and worsening of symptoms despite treatment 
(Bleser, 2006). Objective testing for bowel dysfunction include Anorectal Manometry, the 
Balloon Expulsion Test, Defecography and Colonic Transit Studies.  
Anorectal Manometry is used to assess basal pressure in the rectum and anal canal, squeeze 
maximal sphincter pressure, rectal sensation, simulated defecation, inhibitory reflex, and 
presence of paradoxical contraction of the puborectal musculature (Munteis et al. 2008). The 
Balloon Expulsion Test is used to quantify the ability of a patient to evacuate a water-filled 
(usually 50 ml) balloon. It can serve as a functional marker in biofeedback programs for 
pelvic floor retraining (Gill, Chia, Henry & Shorvon, 1994; Locke III, Pemberton & Phillips, 
2000). Defecography includes the scintigraphic method used to evaluate anorectal 
angulation and pelvic floor descent during evacuation. Barium defecography is performed 
in conjunction with a standard enema. These tests can determine failure of the anorectal 
angle  to open and degree of pelvic floor descent during defecation (Locke, Pemberton & 
Phillips, 2000). Colonic Transit Studies are used to determine the rate at which fecal residue 
moves through the colon using radiopaque markers (Locke, Pemberton & Phillips, 2000). 
The test provides quantitative information about colonic transit, enables the identification 
and characterization of transit abnormality, and allows assessment of the severity of the 
problem (Ringel, 2003). 
 
Medication Action 
Precautions or 
Contraindications 
Bulk-forming 
 Methylcellulose,    
     Citrucel® 
 Carboxymethyl cellulose 
     sodium 
 Malt soup extract,   
    Maltsupex® 
Partially hyrdrolyxe guar  
    gum   Benerfiber® 
Polycarbophi, FiberCort® 
Contain natural and 
semisynthetic hydrophilic 
polysaccharides and 
cellulose derivative that 
dissolve in the intestinal 
fluid to facilitate passage of 
the intestinal contents and 
stimulate peristalsis. 
Doesn’t affect absorption of 
nutrients. 
Abdominal cramping and 
flatulence may occur. 
Avoid taking a bulking 
agent within 1 to 2 hours of 
taking other medications. 
Drink at least 8 oz of fluid 
with each dose. Acts within 
12 to 24 hours  
Emollients/ Stool 
Softeners 
Docusate sodium, Colace® 
Docusate calcium      
Docusate potassium 
Increase the wetting 
efficiency of intestinal fluid, 
promotes a softer stool, 
helps prevent painful 
defecation and straining.  
May cause diarrhea and 
mild abdominal cramping. 
Avoid use if nausea, 
vomiting, or abdominal 
pain exist. Acts within 24 to 
72 hr.  
Lubricants 
Mineral Oil 
Soften fecal contents by 
coating them, thus 
preventing colonic 
absorption of fecal water. 
Excessive use may impair 
absorption of vitamins A, 
D, E, and K. Acts in 6 to 8 
hours. 
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Medication Action 
Precautions or 
Contraindications 
Saline Laxatives 
(Osmotics) 
Magnesium citrate,  
    Citroma® 
Magnesium hydroxide,  
    Milk of  Magnesium® 
Magnesium sulfate,  
     Epson Salts® 
Polyethylene Glycol,  
     MiraLAX® 
Lactulose 
Produce both secretory and 
motor reactions that draw 
water into the intestine, to 
increase intraluminal 
pressure which in turn 
increases intestinal motility. 
Indicated for acute 
evacuation of the bowel. 
Take on an empty stomach 
as food will delay its action. 
May cause abdominal 
cramping, diuresis, nausea, 
vomiting, and dehydration. 
Acts within 30 minutes to 3 
hours. 
Stimulants   
Senna,  
     Senokot® 
Bisacodyl 
Castor oil 
Increase the propulsive 
peristaltic activity of the 
intestine by local irritation 
of the mucosa or by a more 
selective action on the 
intramural nerve plexus of 
intestinal smooth muscle, 
thus increasing motility. 
Stimulate secretion of water 
and electrolytes in either 
the small or large intestine 
or both. 
Used for simple 
constipation, but not to be 
used for more than 1 week 
unless ordered by a 
physician. May cause 
severe cramping, electrolyte 
and fluid deficiencies, 
enteric loss of protein, 
malabsorption resulting 
from excessive 
hypermotility and 
catharsis, and hypokalemia. 
Usually acts within 6 to 12 
hours or may require up to 
24 hours. 
Suppositories 
Glycerin 
 
Dulcolax 
A hyperosmotic laxative 
that irritates the lining of 
the intestine. Draws water 
into the rectum to stimulate 
a bowel movement. Has a 
direct stimulating effect on 
the network of nerves in the 
large intestine. Provides 
lubrication to promote 
elimination of stool.
Do not use if abdominal 
pain, feel sick, or have 
vomiting. 
Take plenty of fluids while 
taking the medication. 
Usually acts within 30 
minutes 
Enemas 
Mineral Oil 
      
Fleet Enema 
Lubricates the colon and 
allows for added cleansing. 
Pulls water from the body 
into the bowel which helps 
to soften the stool and 
cause a bowel movement. 
Enema solutions can cause 
fluid and electrolyte 
disturbances in the blood if 
used on a chronic basis. 
May cause anal irritation, 
diarrhea, gas, nausea, 
stomach, cramps. Acts 
within 5 to 15 minutes. 
Table 4. Medications used to Manage Constipation 
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7.3 Components of a bowel program: Fecal incontinence 
As was noted for the Bowel Program described for constipation, the development of the 
bowel program for fecal incontinence should be comprehensive and individualized to 
include the physical abilities of the patient, availability of care, the chosen lifestyle and 
preferences of the patient and education of the patient and caregiver (Coggrave, et al. 2006). 
Except for fecal incontinence caused by viral, bacterial or protozoal infections, treatment for 
fecal incontinence commonly experienced by MS patients should entail a conservative 
approach. These include dietary considerations, medications that have diarrheal effects, 
toileting routine, incontinent pads, biofeedback, antidiarrheal medications and possibly anal 
plugs or sacral nerve stimulation.  
7.3.1 Dietary considerations 
Persons with MS could benefit from monitoring their food intake through use of a food diary 
to determine if certain foods may be related to fecal incontinence. A food diary should list 
what and how much one eats and when one has an incontinent episode to determine if a 
pattern between certain foods and incontinence occur. Known foods that have been associated 
with fecal incontinence include milk, egg, peanut, tree nuts, fish, shellfish, soy seeds, wheat, 
fruits and vegetables (Sicherer, 2011). Avoidance of fatty foods, foods rich in simple sugars, 
spicy foods, and caffeine may be helpful in controlling fecal incontinence (Walker, 2006). 
Hinds and Wald (1989) suggest reducing fiber intake if incontinence of solid stool occurs. 
7.3.2 Medications associated with fecal incontinence 
Medications given to control various MS-related symptoms and/or conditions unrelated to 
MS may contain diarrheal properties. Table 3 lists several of these medications.  
7.3.3 Toileting regime to control fecal incontinence 
Although patients are strongly encouraged to establish a daily time for defecation 
(DasGupta & Fowler, 2003) fewer than five percent of MS patients with fecal incontinence 
reported using a daily time for defecation (Gulick, 2010). Hinds and Wald (1989) suggest 
establishing a routine schedule of enemas or suppositories (e.g., once a week) to keep the 
rectum empty. 
7.3.4 Use of incontinent pads 
Incontinence pads have been shown to be used by approximately one third of MS patients 
who experience fecal incontinence (Gulick, 2010). Use of these pads can conceal the 
incontinence problem from others particularly if the quantity of lost stool is small. When 
soiling of the pad occurs, it needs to be changed in order to prevent skin breakdown of the 
perineum and/or buttocks that can result in incontinence dermatitis and/or pressure ulcers 
(Whitely, 2007). 
7.3.5 Biofeedback for fecal incontinence 
This intervention may be helpful by improving the strength of pelvic floor muscles and 
rectal sensory perception to improve anorectal coordination (Nordenbo, et al. 1996). 
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Biofeedback retraining is more successful in persons with MS with limited disability and a 
non-progressive disease course (Wiesel, et al. 2000). 
7.3.6 Antidiarrheal medications 
These medications remain the main treatment for fecal incontinence. In taking antidiarrheal 
medications patients need to be cautioned about the potential adverse effects of 
dehydration. Antidiarrheal medications have been shown to be used by approximately one 
third of MS patients who experience fecal incontinence (Gulick, 2010). Commonly used 
antidiarrheal medications (Walker, 2006) are shown in Table 5. 
 
Medication Action 
Precautions and/or 
Contraindications 
Loperamide,  
   Imodium® 
Slows intestinal motility, 
allowing absorption of 
electrolytes and water 
through the intestine and 
decreased gastro-intestinal 
secretion. 
Occasional dizziness and 
constipation may occur. 
Infrequent occurrence of 
abdominal pain, abdominal 
distention, nausea, vomiting, dry 
mouth, fatigue, and 
hypersensitivity reactions. 
Bismuth 
Subsalicylate,  
     Kaopectate® 
Reduces the frequency of 
unformed stools, increases 
stool consistency, relieves 
symptoms of abdominal 
cramping, and decreases 
nausea and vomiting. 
Mild tinnitus is a dose-related 
side effect that may be associated 
with moderate to severe salicylate 
toxicity. Discontinue drug if 
tinnitus occurs. The drug may 
interact with other medications, 
such as aspirin, tetracycline and 
quinolone antibiotics. 
 
Diphenoxylate/ 
Atropine,   
Lomotil® 
 
 
 
 
 
Slows intestinal contractions 
and peristalisis allowing the 
body to consolidate intestinal 
contents and prolong transit 
time, thus allowing the 
intestines to draw moisture 
out of the intestinal material 
to stop the formation of loose 
or liquid stools. 
Discontinue drug if one 
experiences extreme thirst, 
decreased urination, muscle 
cramps, or weakness. 
Racecadotril 
   Acetorphan 
   Hidrasec® 
Acts as a peripherally acting 
enkephalinase inhibitor that 
has an antisecretory effect by 
reducing secretion of water 
and electrolytes into the 
intestine 
Shown to promptly and 
significantly reduce total stool 
output in 48 to 72 hours after 
initiation of treatment. Is well 
tolerated in adults and children. 
Table 5. Medications used to Manage Fecal Incontinence 
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7.3.7 Anal plug 
The anal plug has been developed to prevent loss of stool and is a disposable device for 
patients with anorectal incontinence. In a study of 10 patients with incontinence to gas and 
both liquid and solid stool the use of variable anal plugs for three consecutive weeks 
resulted in one patient withdrawing from the study due to discomfort of the anal plug, and 
for the remaining subjects there were no episodes of incontinence during 82% of time in 
which anal plugs were used with a median time of 7 to 12 hours depending on type of plug 
(Mortensen & Humphreys, 1991). Norton and Kamm (1999) evaluated two sizes of anal 
plugs each of which was tested for a two week period in a sample of 20 ambulatory and self-
caring patients with intractable fecal incontinence for solid or liquid stool. Results indicated 
that the majority 14 (70%) could not tolerate a plug due to discomfort but for those that 
could tolerate the plug, it was highly successful at controlling fecal incontinence. Patients 
with neurogenic bowel dysfunction and have attenuated anorectal sensation may tolerate 
the presence of the anal plug (Emmanuel, 2010). Research is needed to determine if the use 
of anal plugs are helpful in controlling fecal incontinence in persons with MS.  
7.3.8 Sacral Nerve Stimulation 
Sacral nerve stimulation (SNS) for patients with severe fecal incontinence undergo 
implantation with a quadripolar electrode and pulse generator placed subcutaneously in the 
gluteal area (Tjandra, Chan, Yeh & Murray-Green, 2008). Compared to a control group who 
received medical therapy that comprised bulking agents, pelvic floor exercises, and dietary 
management, fecal incontinence was greatly improved with chronic SNS immediately after 
implantation and was sustained during the 12 month follow-up period in a randomized 
study of non-MS patients with severe fecal incontinence (Tjandra et al. 2008). Adverse 
events with SNS included pain at implant site which resolved after percutaneous aspiration 
and excessive tingling in the vaginal region.  Research is needed to determine if the use of 
SNS is helpful in controlling fecal incontinence in persons with MS. 
8. Outcome of various management strategies for bowel dysfunction in 
persons with MS 
Possibly due to the multiplicity of causes of bowel dysfunction in persons with MS the 
outcome from the various treatment/intervention approaches have not yielded very 
satisfactory results. In a study of bowel dysfunction among persons with MS, Gulick (2010) 
noted that 54.1% (99/183) reported their constipation had worsened over time; 38.6% 
(22/57) reported their fecal incontinence worsened over time; and 71.8% (117/163) who 
experienced both constipation and fecal incontinence reported their constipation problem 
had worsened over time. Additionally, a survey of MS respondents who reportedly used a 
wide range of strategies to manage their bowel problems indicated that few of them were 
rated as very helpful (Norton & Chelvanayagam, 2010). 
Many conditions and treatments that accompany MS over its long term illness trajectory may 
as a single entity or in combination lead to bowel dysfunction. These conditions frequently 
include ambulation difficulty, spasticity, fatigue, depression, urinary incontinence and various 
medications. In addition to MS related causes of bowel dysfunction there may be other health 
problems unrelated to MS that can cause bowel dysfunction.  
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Studies clearly acknowledge the adverse impact that bowel dysfunction has on the quality 
of life of persons with MS as the various bowel problems greatly interfere with the person’s 
physical and social activities, family relationships, which also lead to the development of 
considerable emotional distress (Gulick, 1997; Norton & Chelvanayagam, 2010; Nortvedt, 
Riise, Frugard, Mohn, Bakke, Skar, Nyland, Glad & Myhr, 2007; Wollin, Bennie, Leech, 
Windsor, & Spencer, 2005). With regard to bowel dysfunction, persons with MS report that 
fecal incontinence has a significantly greater negative impact on their quality of life than 
constipation (Gulick, 2011; Norton & Chelvanayagam, 2010). Of the various MS related 
symptoms, respondents in the study by Norton and Chelyanayagam reported that bowel 
dysfunction and bowel management had the greatest negative impact on their quality of 
life. 
9. Conclusion 
Bowel dysfunction consisting of constipation and/or fecal incontinence is common in 
persons with MS. Causes of bowel dysfunction may be due to neurological lesions in the 
CNS or by non-neurological causes. The relapsing-remitting or progressive MS course may 
result in acute or chronic symptoms of constipation and/or fecal incontinence. Subjective 
and objective assessments of bowel symptoms using a team of specialists to determine the 
causes, appropriate treatment/intervention with ongoing monitoring of the condition is 
essential. Further studies with persons with MS are needed to determine the effectiveness of 
treatments/interventions given to improve bowel functions among those with bowel 
problems while controlling for confounding issues. Further study is also needed to 
determine the effectiveness of using objective laboratory procedures to identify or rule out 
specific causes of bowel problems. 
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